atazanavir myl atazanavir (as sulfate) 300 mg capsule bottle
alphapharm pty ltd - atazanavir sulfate -
atazanavir myl atazanavir (as sulfate) 200 mg capsule bottle
alphapharm pty ltd - atazanavir sulfate -
atazanavir sulfate powder
granules india ltd - atazanavir sulfate (unii: 4mt4vie29p) (atazanavir sulfate - unii:4mt4vie29p) -
atazanavir- atazanavir capsule
camber pharmaceuticals, inc. - atazanavir sulfate (unii: 4mt4vie29p) (atazanavir - unii:qzu4h47a3s) - atazanavir capsules are indicated in combination with other antiretroviral agents for the treatment of hiv-1 infection in adults and in pediatric patients 6 years and older weighing at least 15 kg. limitations of use: • atazanavir are not recommended for use in pediatric patients below the age of 3 months due to the risk of kernicterus [ see use in specific populations ( 8.4) ]. • use of atazanavir with ritonavir in treatment-experienced patients should be guided by the number of baseline primary protease inhibitor resistance substitutions [ see microbiology ( 12.4)] . atazanavir capsules are contraindicated: • in patients with previously demonstrated clinically significant hypersensitivity (eg, stevens- johnson syndrome, erythema multiforme, or toxic skin eruptions) to any of the components of atazanavir capsules [ see warnings and precautions (
atazanavir teva 150 mg capsules, hard
teva b.v. - atazanavir sulfate - capsule, hard - 150 milligram(s) - protease inhibitors; atazanavir - protease inhibitor - atazanavir teva capsules, co-administered with low dose ritonavir, are indicated for the treatment of hiv-1 infected adults and paediatric patients 6 years of age and older in combination with other antiretroviral medicinal products. based on available virological and clinical data from adult patients, no benefit is expected in patients with strains resistant to multiple protease inhibitors ( 4 pi mutations). there are very limited data available from children aged 6 to less than 18 years
atazanavir teva 200 mg capsules, hard
teva b.v. - atazanavir sulfate - capsule, hard - 200 milligram(s) - protease inhibitors; atazanavir - protease inhibitor - atazanavir teva capsules, co-administered with low dose ritonavir, are indicated for the treatment of hiv-1 infected adults and paediatric patients 6 years of age and older in combination with other antiretroviral medicinal products. based on available virological and clinical data from adult patients, no benefit is expected in patients with strains resistant to multiple protease inhibitors ( 4 pi mutations). there are very limited data available from children aged 6 to less than 18 years
atazanavir teva 300 mg capsules, hard
teva b.v. - atazanavir sulfate - capsule, hard - 300 milligram(s) - protease inhibitors; atazanavir - protease inhibitor - atazanavir teva capsules, co-administered with low dose ritonavir, are indicated for the treatment of hiv-1 infected adults and paediatric patients 6 years of age and older in combination with other antiretroviral medicinal products. based on available virological and clinical data from adult patients, no benefit is expected in patients with strains resistant to multiple protease inhibitors ( 4 pi mutations). there are very limited data available from children aged 6 to less than 18 years (
atazanavir teva capsules hard 150mg
teva b.v. swensweg 5, 2031 ga haarlem, netherlands - atazanavir sulfate - hard capsule - atazanavir sulfate 150 mg - antivirals for systemic use
atazanavir teva capsules hard 200mg
teva b.v. swensweg 5, 2031 ga haarlem, netherlands - atazanavir sulfate - hard capsule - atazanavir sulfate 200 mg - antivirals for systemic use
atazanavir teva capsules hard 300mg
teva b.v. swensweg 5, 2031 ga haarlem, netherlands - atazanavir sulfate - hard capsule - atazanavir sulfate 300 mg - antivirals for systemic use